The Report Ocular Drug Delivery Technology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz. This report on the Global Ocular Drug Delivery Technology market analyzes the current and future scenario of the global market. Rise in private and public funding for R&D of novel drug delivery technologies, increase in prevalence of macular degeneration & diabetic retinopathy, and favorable regulatory scenario for introduction of innovative technologies are boosting the growth of the Global Ocular Drug Delivery Technology market. Rising demand for targeted drug delivery to the affected ocular tissue, and elimination of drug due to nasolacrimal drainage system when administered via topical route are some of the factors expected to drive the growth of Global Ocular Drug Delivery Technology market during the forecast ...
Plants are natures remedies and have been used by human beings on earth since ancient times for food and medicine. Today there are global movements towards finding of herbal medicaments in plants to bring them in market via a suitable drug delivery system for mankind. The basic thought behind it is treatment of each disease is hidden in nature. However, delivery of herbal drugs also requires modification with the purpose to achieve sustain release, to increase patient compliance etc. previously herbal drugs could not attract scientists towards the modifications of novel drug delivery systems due to processing, standardizing, extracting and identification difficulties. But now days with the advancement in the technology, novel drug delivery systems (NDDS) open the door towards the development of herbal novel drug delivery system. With use of advance techniques protection from toxicity, enhancement in stability, improved bioavailability of herbal formulations, protection from physical and ...
The Center for Business Intelligence (CBI) Summit on Novel Drug Delivery Strategies will convene industry leaders in the drug delivery, business development, lifecycle management and the commercialization arena to discuss the growing drug delivery market. The conference will examine the effects of incorporating a novel drug delivery system into the product lifecycle in early stages of development by assessing markets prior to commercialization.. Novel drug delivery systems are brought to the market through strategic alliances between pharmaceutical, biotech and drug delivery companies. Licensing agreements are an integral part of that process and their complexity varies with the value of the technology and the stage of development it is introduced. On Day 1 of the conference, Foley & Lardner LLP Associate Michael Yamauchi will lead the session, Analyzing Licensing Agreement Strategies through Interactive Mock Case Study Discussions. This executive exchange facilitates open discussion on key ...
Further in the Controlled-Release Drug Delivery Technology Market research report, following points are included along with in-depth study of each point:. • Production Analysis- Production of the Controlled-Release Drug Delivery Technology is analysed with respect to different regions, types and applications. Here, price analysis of various Controlled-Release Drug Delivery Technology Market key players is also covered.. • Sales and Revenue Analysis- Both, sales and revenue are studied for the different regions of the global Controlled-Release Drug Delivery Technology Market. another major aspect, price, which plays important part in the revenue generation is also assessed in this section for the various regions.. • Supply and Consumption- In continuation with sales, this section studies supply and consumption for the Controlled-Release Drug Delivery Technology Market. This part also sheds light on the gap between supple and consumption. Import and export figures are also given in this ...
Market experts suggest that, There is a continuous growth in the market of drug delivery systems and will continue to grow at an impressive rate in future also. The novel drug delivery technologies enable to formulate the novel drug delivery devices by incorporating the drug molecules into new delivery systems, thus providing numerous therapeutic and commercial advantages. It was observed that NDDS market was segmented on the basis of route of administration, type of carrier and geographical region. In route of administration segment, injectable drug delivery system was observed as the largest market in 2015 followed by oral drug delivery system. Injectable drug delivery system comprises of several benefits over other dosage forms in cases such as unconsciousness, nausea, in emergency clinical episodes. The injectable administration route is the most common and efficient for delivery of active drug substances with poor bio-availability and the drugs with a narrow therapeutic index. On the basis ...
Michael J. Rathbone This two volume Second Edition of Modified-Release Drug Delivery Technology describes the anatomical, physiological, pharmaceutical, and technological aspects of oral, colonic and rectal, ocular, oral mucosal, dermal and transdermal, nasal, vaginal, and pulmonary delivery routes.. Modified-Release Drug Delivery Technology provides insight and critical assessment of the many available and emerging modified release drug delivery systems for their current and future value.. Modified-Release Drug Delivery Technology is available as a 2-volume set or each volume may be purchased individually.. Contents and information on Volume One ...
A team of UC Davis scientists has shown in experimental mouse models that a new drug delivery system allows for administration of three times the maximum tolerated dose of a standard drug therapy for advanced bladder cancer, ...
Scientists in Syracuse Universitys Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.
Novel drug delivery systems are now a days is creating a new interest in development of drug deliveries. Vesicular drug delivery system is also a part of these novel drug delivery systems. TDDS is the permeability of the skin, it is permeable to small molecules, lipophilic drug and highly impermeable to the macromolecules and hydrophilic drugs. Recent approaches have resulted in design of two vesicular carriers, ethosomes and ultra flexible lipid based elastic vesicles, transferosomes. Transferosomes have recently been introduced, which are capable of transdermal delivery of low as well as high molecular weight drugs. This offers several potential advantages over conventional routes like avoidance of first pass metabolism, predictable and extended duration of activity, minimizing undesirable side effects, utility of short half life drugs, improving physiological and pharmacological response and have been applied to increases the efficiency of the material transfer across the intact skin, by the use of
Summary. Latest report, Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during the Forecast Period discusses the drug delivery technologies and trends in the market and the evolving business strategies being adopted and leveraged by companies globally.. The ultimate goal of drug delivery research is to develop formulations and devices that can be used in clinical applications to treat various diseases. Delivering a drug with the desired release kinetics requires an understanding of the underlying physicochemical properties of the drug, which determine the type of delivery material and drug release mechanism.. Numerous parameters need to be considered, and their inter-dependence has to be taken into account to develop successful drug delivery systems for the intended applications. It is important to understand the complexity associated with the development of a drug delivery system that can ultimately be ...
TY - JOUR. T1 - Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. AU - Cheng, Yu. AU - Samia, Anna C.. AU - Meyers, Joseph D.. AU - Panagopoulos, Irene. AU - Fei, Baowei. AU - Burda, Clemens. PY - 2008/8/13. Y1 - 2008/8/13. N2 - A highly efficient drug vector for photodynamic therapy (PDT) drug delivery was developed by synthesizing PEGylated gold nanoparticle conjugates, which act as a water-soluble and biocompatible cage that allows delivery of a hydrophobic drug to its site of PDT action. The dynamics of drug release in vitro in a two-phase solution system and in vivo in cancer-bearing mice indicates that the process of drug delivery is highly efficient, and passive targeting prefers the tumor site. With the Au NP-Pc 4 conjugates, the drug delivery time required for PDT has been greatly reduced to less than 2 h, compared to 2 days for the free drug.. AB - A highly efficient drug vector for photodynamic therapy (PDT) drug delivery was ...
The global novel drug delivery systems (NDDS) in cancer therapy market size was valued at USD 4.31 billion in 2016 and is projected to grow at a CAGR of 22.9% during the forecast period. Worldwide increasing incidence of cancer, availability of research funding, increase in awareness about alternative methods for treatment, and favorable reimbursement scenarios in developed nations are some of the key drivers of this market.
World Congress on Pharmaceutics & Novel Drug Delivery Systems on Jun 15, 2020 in Zurich, Switzerland at Zurich, Switzerland. Ology Mavens is hosting...
Novel Drug Delivery Systems Market Was Valued At USD 165.4 Bn In 2015, And Is Expected To Reach USD 202.5 Bn By 2022, Expanding At A CAGR Of 2.7% From 2016 To 2022
http://www.marketsandmarkets.com/Market-Reports/drug-delivery-technologies-market-1085.html. Drug delivery technologies alter the release of drug so as to facilitate optimum efficacy and safety.Such technologies simplify the dosing regimen and reduce side-effects, thus boosting patient compliance. The global drug delivery market is divided into nine segments, namely, oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable,andtransmucosal. Drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.. The major drivers of this market are patent expiries of certain blockbuster drugs, growing demand for self administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer, growing focus on pediatric and geriatric patients, and advancing technology.However, ...
TY - JOUR. T1 - Standpoint on the priority of TNTs and CNTs as targeted drug delivery systems. AU - Ranjous, Yasmin. AU - Regdon, Géza. AU - Pintye-Hódi, K.. AU - Sovány, Tamás. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Conventional drug delivery systems have limitations according to their toxicity and poor solubility, bioavailability, stability, and pharmacokinetics (PK). Here, we highlight the importance of functionalized titanate nanotubes (TNTs) as targeted drug delivery systems. We discuss the differences in the physicochemical properties of TNTs and carbon nanotubes (CNTs) and focus on the use of functionalization to improve their characteristics. TNTs are promising materials for drug delivery systems because of their superb properties compared with CNTs, such as their processability, wettability, and biocompatibility. Functionalization improves nanoparticles (NPs) via their surface modification and enables them to achieve the targeted therapy.. AB - Conventional drug delivery systems have ...
Niosomes are non-ionic surfactant based liposomes. Niosomes, the novel drug delivery system are self assembled vesicles primarily of synthetic surfactant incorporated with cholesterol as an excipient. They are the vesicles formed by hydrating the cholesterol and non-ionic surfactant. The main aim of niosome includes use of drug in efficient manner which includes reduced dose, reduced side effect, reduced dosage frequency, greater patient compliance and maximum concentration at the site of action so, that under exposure to the entire body. It includes higher therapeutic efficiency and reduced side effect. Niosomes are thought to be the better candidates drug delivery system due to the various factor like cost, stability, etc. various types of drug delivery is possible using niosomes like targetting drug action, ophthalmic, topical, parenteral, etc. Drug delivery potential of niosomes can be enhanced by using novel concept like proniosomes, discomes and aspasomes. Niosomes serves better aid in ...
DUBLIN, May 21, 2021 /PRNewswire/ -- The Cardiovascular Drug Delivery - Technologies, Markets & Companies report from Jain PharmaBiotech has been added to ResearchAndMarkets.coms offering. The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. The role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.. Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases.. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of ...
The promise of drug delivery strategies is in their potential to improve current treatments and create opportunities for experimental therapy. Drugs that ...
ABSTRACT. Development of new drug delivery system has become the requirement of todays pharmaceutical industry. As the number of off-patent drugs and cost of new drug development increases, pharmaceutical companies are managing the life cycles of their products (from product launch to their withdrawal from the market) by adopting new and innovative delivery systems. This gives the pharmaceutical industry another chance to make the most of their current products. Oral route is the most preferred route for administration of drugs as the administration is easy and economic. But the problem is the loss of their functions due to the short residence in the body. About 80% of the administered drugs are excreted without being absorbed. This article comprehensively explains need of hydrogels and its modifications to prolong the residence time of drugs in the body, with brief introduction of associated other drug delivery systems.. Keywords: Superporous Hydrogels, Absorption Window, Stomach Specific Drug ...
drug delivery system for sale - 107901 - drug delivery system wholesalers & drug delivery system manufacturers from China manufacturers.
Adult neural stem cells to develop a new stem cell-based drug delivery therapy that may ultimately help treat a variety of inherited genetic disorders like Hunter syndrome.
Thank you for your interest in spreading the word on Stroke.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ...
Wim Jiskoot graduated as a pharmacist in 1987 and received his PhD degree in 1991 at Utrecht University on pharmaceutical aspects of monoclonal antibodies. As a postdoctoral fellow at the University of Utah (1991-1993) he studied protein-ligand interactions using biophysical techniques. From 1994-1998 he was head of the Department of Bacterial Vaccine Development at the National Institute of Public Health and the Environment (RIVM), Bilthoven. In 1998 he became a staff member at the Department of Pharmaceutics, Utrecht University, where he focused his research on formulation and physicochemical characterization of therapeutic proteins and vaccines. In March 2006 he was appointed as full professor at the Division of Drug Delivery Technology, LACDR, and as the coordinator of the Biologics Research Platform Leiden (BRPL). His current research is concentrated on two themes: (1) formulation and unwanted immunogenicity of therapeutic proteins and (2) vaccine delivery.. ...
Wim Jiskoot graduated as a pharmacist in 1987 and received his PhD degree in 1991 at Utrecht University on pharmaceutical aspects of monoclonal antibodies. As a postdoctoral fellow at the University of Utah (1991-1993) he studied protein-ligand interactions using biophysical techniques. From 1994-1998 he was head of the Department of Bacterial Vaccine Development at the National Institute of Public Health and the Environment (RIVM), Bilthoven. In 1998 he became a staff member at the Department of Pharmaceutics, Utrecht University, where he focused his research on formulation and physicochemical characterization of therapeutic proteins and vaccines. In March 2006 he was appointed as full professor at the Division of Drug Delivery Technology, LACDR, and as the coordinator of the Biologics Research Platform Leiden (BRPL). His current research is concentrated on two themes: (1) formulation and unwanted immunogenicity of therapeutic proteins and (2) vaccine delivery.. ...
MUNICH, Germany, June 6, 2017 - Brainlab and Medicenna Therapeutics Corp (the Company or Medicenna; TSXV MDNA) jointly announced today that recurrent Glioblastoma (rGB) patients in a Phase 2b clinical trial of MDNA55, a targeted immunotherapy agent, have been treated at three clinical centers in the United States using innovative drug delivery technology from Brainlab. The investigators used convection enhanced delivery (CED) to inject MDNA55, together with an imaging agent, directly into the tumor. When combined with real-time image guided MRI, CED allows delivery of MDNA55 at high concentrations into the tumor tissue while avoiding exposure to the rest of the body. The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the United States.. Precise targeting is an integral part in the treatment of brain tumors to achieve significant coverage. iPlan® Flow planning software from Brainlab helps determine trajectories for drug ...
Adherence is crucial in medical glaucoma therapy, although half of the patients skip eyedrops. In recent years alternative drug-delivery systems have been developed. One of the most promising seems the contact lens (CL). This systematic review aims to present the in vivo efficacy of different CL drug-delivery systems. A total of 126 studies were identified following a literature search adhering to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. After full-text evaluation, 19 studies about CL drug-delivery systems were included. To date, the following drug-delivery systems have been investigated in vivo: drug-soaked CL, CL with physical barriers (vitamin E), molecularly imprinted CL, CL with implants, and nanoparticle-loaded CL. Nanoparticle-loaded CL and CL with implants seem the most promising drug-delivery systems, although initial burst drug release and patient acceptance may limit their widespread use in current practice. Clinical trials are warranted to
New drug delivery methods have potential to improve compliance through ease of use, but have brought up some new questions. Is reconfiguring an injected insulin into an inhaled version, for example, just a way to relaunch a product, or does the invention provide more than a me-too product?
DecisionDatabases.com adds a report on 2016 Global Drug Delivery Technologies Market Status, 2011-2022 Market Historical and Forecasts, Professional Market Research Report. This research study is segmented on the bases of applications, technology and geography.
London (PRWEB) October 29, 2013 -- Report Details Drug delivery technology - discover technological and commercial prospects What does the future hold for
Research and Markets has announced the addition of the "Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Ma
Global Nasal Drug Delivery Technologies Market key players are Merck & Co., Inc., Novartis AG, J & J, Pfizer Inc., AstraZeneca, AptarGroup and others.
The global nasal drug delivery technology market is projected to reach USD 64.20 billion by 2021 from USD 44.00 billion in 2016, at a CAGR of 6.5%
A dispense interface for use with a drug delivery device. The dispense interface comprises a main outer body and an inner body. The inner body may be configured for connection to a drug delivery device and defines a first reservoir and a second reservoir. A first piercing needle is in fluid communication with the first reservoir and positioned for piercing a first cartridge of a drug delivery device. A second piercing needle is provided and in fluid communication with the second reservoir and positioned for piercing a second cartridge contained with a drug delivery device. A manifold is positioned adjacent the inner body and comprises a fluid groove arrangement. A valve arrangement is positioned between the inner body and the manifold and controls fluid communication of a first fluid contained in the first cartridge and a second fluid contained in the second cartridge by way of the fluid groove arrangement to a holding chamber. The dispense interface may further comprise a lockout preventing dispense
The present invention relates to a drug delivery system with two-step targeting, which comprises a combination: (a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissues; and (b) a drug enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nuclei of specific target cells. Furthermore, the invention relates to a method of cancer therapy in which the above drug delivery system is administered to a cancer patient. The goal is to treat or analyse both large tumour masses as well as small tumour cell clusters and single spread tumour cells. According to the invention, drug uptake in tumours will be markedly increased at the same time as the interaction of the drug with healthy organs and tissues can be minimized. The invention gives potential to convert palliative into curative treatment.
The global Pulmonary Drug Delivery Systems Market report provides an accurate investigation of the different patterns and parameters affecting the industrial growth of the Pulmonary Drug Delivery Systems market at a global level. An assessment of the effect of the current situation and trends in the market is additionally included to provide an overview of the markets future position. The report provides the detailed information related to the global Pulmonary Drug Delivery Systems market dynamics and demonstrates superior forecast for the development of the market and its key competitors 3M, GSK, AstraZeneca, Cipla, Chiesi, Boehringer Ingelheim, Aptar, Novartis, Philips Respironics, Omron Healthcare, PARI, Skyepharma, CareFusion, Shanghai Huarui, Taian Character, Chia Tai Tianqing based on consistent information.. Apply here for the sample copy of the report @: www.reportsbuzz.com/request-for-sample.html?repid=83030. Furthermore, The report presents a detailed segmentation Nebulizers, Dry ...
An extended release gastro-retentive drug delivery system of Valsartan. The drug delivery system contains a release portion containing the Valsartan, a gastro-retentive portion for retaining the drug
Research in novel drug delivery systems is being explored competitively in order to attain maximum therapeutic effect while minimizing the adverse effects. Despite several advancements in pharmaceutical formulations, one of the major challenges still persisting is sustained drug release. Microencapsulation enacts as an intelligent approach with a strong therapeutic impact and is in demand globally in medical technology due to its specific and attractive properties, including biocompatibility, stability, target specificity, uniform encapsulation, better compliance, and controlled and sustained release patterns that are responsible for diminishing the toxicity and dosage frequency. Microparticles are successful delivery systems that encapsulate both water-insoluble and sparingly water-soluble agents to elicit their efficacy with a great potential attributed to their unique properties: particle size, shape, structure, drug loading, entrapment efficiency, porosity, and release profile. Several ...
Designing new drug delivery systems requires tight control of drug release kinetics. Historically, polymers have been strong contenders in the field. However, achieving a narrow polydispersity and reducing batch-to-batch variability in synthesis can be difficult. Therefore researchers have expanded to other materials such as lipids, which mat have more favorable drug release properties. Lipids are a chemically unique category of molecules that plays a role in functionality and architecture of all living cells. Thus when used as materials for design of drug delivery systems, they will be considered biodegradable and biocompatible. In addition they offer more robust control over design of molecular architecture and thus directly impact the release kinetics of model drugs. The aim of this study was to better understand the mass transport mechanism involved in controlled release of a model drug from lipid based parenteral delivery systems. A family of dihydroxyacetone (DHA) derived symmetrical ...
This is part of the CCB Spring Seminar Series 2016.. Abbi Abdel Rehim/Sabrya Carim, University of Manchester A Novel Approach for Attaching Targeting Ligands to Liposomal Drug Delivery Systems/IPIP, a novel player in cell division Lab: Stephen High/Martin Lowe. ...
The invention relates to a process for preparing a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a spray coating comprising a testosterone.
Scientific, peer-reviewed Dermatology article, indexed with MEDLINE/PubMed: Delivery Technologies Matter: Maximizing Efficacy and Minimizing Side Effects : No abstract available
To prevent water from flooding the structure and causing an immediate release of the drug, Grinstaff and his colleagues designed the air-filled, mesh-like material to be superhydrophobic-so water-resistant that droplets of water barely touch the surface, forming beads similar to those that appear on a freshly waxed car. They produced the porous polymer mesh using a process called electrospinning, which overlays micron-sized fibers upon one another. To control the rate of drug release, they adjusted chemical and physical properties of the material so that the entrapped air is loosely or tightly held. The more tightly held the air is within the structure, the harder it is for water to displace it, the slower the release, and the longer the treatment duration. Loaded with a widely used anti-cancer drug called SN-38 in in vitro experiments, the polymer mesh and internal air pocket proved to be robust and effective against lung cancer cells in solution for more than 60 days, indicating its ...
Lumenis Ltd. introduced an ophthalmic laser delivery technology and slit lamp biomicroscope system (InSight) at the recent annual meeting of the American Academy of Ophthalmology.
Now a day the use of herbal medicines has been increased all over the world due to their excellent and miraculous therapeutic effects and fewer side effects as compared to the modern medicines. Most of phytoconstituents of herbal extracts are water soluble and poorly miscible with oils and other lipids. Lipid solubility and molecular size of phytoconstituents are the major limiting factors for molecule to pass the biological membrane to be absorbed systemically following the oral or topical administration. The bioavailability of phytoconstituents can be increased by use of novel drug delivery system, which can increase the phytoconstituents solubility in gastrointestinal fluid as well as capacity to cross lipid rich biological membrane. Complexation of phytoconstituents with phospholipids or phosphotidylcholine results in novel drug delivery system called Phytosomes. The term phytosomes is coined from two different terms: phyto meaning plant and some meaning cell like. Phytosomes are small in size
The statements, opinions and data contained in the journal International Journal of Molecular Sciences are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations ...
MDC Connects 2021. In this webinar, you will hear from the pioneers developing complex medicines and the challenges presented and overcome.
Local drug delivery medical devices are utilized to deliver therapeutic dosages of drugs, agents or compounds directly to the site where needed. The local drug delivery medical devices utilize various materials and coating methodologies to maintain the drugs, agents or compounds on the medical device until delivered and positioned.
Global Intranasal Drug Delivery Devices Market by Manufacturers, Countries, Type and Application, Forecast to 2023. Intranasal drug delivery system is a medical device used for the administration of drugs for the treatment of local diseases in the nose and paranasal sinus such as allergic and non-allergic rhinitis and sinusitis. Intranasal Drug Delivery Devices are medical devices used for drug delivery through noses. Scope of the Report: This .... February 2018 , $3480 ,View Details>> ...
This independent 125 pages report guarantees you will remain better informed than your competition. With over 170 tables and figures examining the Sustained Release Ocular Drug Delivery Systems market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2025.. The report provides a basic overview of the Sustained Release Ocular Drug Delivery Systems industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.. Primary sources are mainly industry experts from core and related industries, and suppliers, manufacturers, distributors, service providers, and organizations related to all segments of the industrys supply chain. The bottom-up approach was used to estimate the Global market size of Sustained Release Ocular Drug Delivery Systems Market based on end-use ...
A multidisciplinary approach is increasingly being adapted by the Pharmaceutical industry to tackle several challenges in developing efficacious treatment solutions. The field of Ophthalmology is no less different. Treatise on Ocular Drug Delivery is a unique collection of information put together by various experts in the field. One of the major goals behind this volume is to link clinical information with the current strategies employed in ocular drug delivery. This monograph covers a range of topics on ocular pharmacology. Chapters in the e-book cover several aspects of drug delivery research such as the biochemical background of specific eye diseases, challenges for ocular drug delivery, the role of influx and efflux transporters, novel drug delivery systems, pharmacokinetics, regulatory aspects, and patenting opportunities for researchers. This E-Book would serve as a suitable reference for pharmacy graduates, medical students, professional scientists and ophthalmic clinicians in academic ...
According to a new market report published by Transparency Market Research Pulmonary Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019, the global pulmonary drug delivery systems market was valued at USD 21.03billion in 2012 and is expected to grow at a CAGR of4.5% from 2013 to 2019, to reach an estimated value of USD 28.70billion in 2019.. Browse Global Pulmonary Drug Delivery Systems Market Report with Full TOC at http://www.transparencymarketresearch.com/pulmonary-drug-delivery-systems.html. Pulmonary drug delivery systems use the respiratory tract to deliver medications to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The history of use of these systems dates back to over 60 years ago, when these systems were initially indicated for treating only respiratory ...
Principal Investigator:KUZUYA Masayuki, Project Period (FY):1992 - 1993, Research Category:Grant-in-Aid for General Scientific Research (C), Research Field:Physical pharmacy
Carboxymethyl-chitosan/Poly(amidoamine) Dendrimer Nanoparticles as Intracellular Drug Delivery Systems in Central Nervous System Regenerative Medicine: Effects on Neurons/Glial Cell Viability/Proliferation and Internalization Efficiency ...
Global Drug Delivery Technologies Market Size, Status and Forecast 2025 is a market research report available at US $3300 for a Single User PDF License from RnR Market Research Reports Library.
Various efforts in ocular drug delivery have been made to improve the bioavailability and to prolong the residence time of drugs applied topically onto the eye. . The present presentation includes | Basics of drug delivery systems | General aspects for design and development of DDS | General concepts of ocular drug delivery routes | various pros and cons of ocular drug therapy
TY - JOUR. T1 - Liposomal drug delivery system. AU - Maruyama, Kazuo. AU - Kennel, Stephen. AU - Huang, Leaf. PY - 1990/8/1. Y1 - 1990/8/1. N2 - We have recently described an immunoliposome targeting system which involves the use of monoclonal antibodies specific for the pulmonary endothelial cells. We have employed the antibodies, 34A and 201B, which bind to a surface glycoprotein, gp112, which is specifically expressed in high concentrations in the capillary endothelial cells of the mouse lung. Intravenously injected immunoliposomes (34A- or 201B-liposomes) to the mice gain direct access and bind efficiently to the lung. Approximately 50% of the injected dose was accumulated in the lung for 34A-liposomes which contained an average of 935 antibody molecules per liposome. Lung accumulation of 34A-liposomes is completely blocked by a preinjection of free antibody 34A, indicating that the immunoliposome accumulation at the target site is immunospecific. The level of lung accumulation increases ...
A transdermal drug delivery device for the controlled transdermal delivery of an active pharmaceutical agent. The device comprises a drug delivery device comprising an active pharmaceutical agent and a means for its controlled delivery through the skin; and (B) a silicone pressure sensitive adhesive for maintaining contact between the device and the skin of a wearer. The silicone pressure sensitive adhesive comprises silicone resin copolymer and a polydiorganosiloxane and has a silanol concentration in the range of between about 8000 and about 13,000 ppm. The present invention also relates to methods for producing the above silicone pressure sensitive adhesive compositions.
Based on the results, drug loaded solid lipid nanoparticles can provide an alternative to the current available therapy in hypertension by solving the practical problems of poor solubility, low oral absorption and reduced bioavailability
TY - JOUR. T1 - Sustained release nitric oxide releasing nanoparticles. T2 - Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. AU - Friedman, Adam J.. AU - Han, George. AU - Navati, Mahantesh S.. AU - Chacko, Manju. AU - Gunther, Leslie. AU - Alfieri, Alan. AU - Friedman, Joel M.. N1 - Funding Information: The work was partially supported by DOD Grant DAMD17-03-1-0127. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2008/8. Y1 - 2008/8. N2 - A new platform using biocompatible materials is presented for generating powders comprised of nanoparticles that release therapeutic levels of nitric oxide (NO) in a controlled and sustained manner. The capacity of these particles to retain and gradually release NO arises from their having combined features of both glassy matrices and hydrogels. This feature allows both for the generation of NO through the thermal reduction of added nitrite by glucose and for the retention of the ...
Nanoparticles have attracted increasing attention for local drug delivery to the inner ear recently. Bovine serum albumin (BSA) nanoparticles were prepared by desolvation method followed by glutaraldehyde fixation or heat denaturation. The nanoparticles were spherical in shape with an average diameter of 492 nm. The heat-denatured nanoparticles had good cytocompatibility. The nanoparticles could adhere on and penetrate through the round window membrane of guinea pigs. The nanoparticles were analyzed as drug carriers to investigate the loading capacity and release behaviors. Rhodamine B was used as a model drug in this paper. Rhodamine B-loaded nanoparticles showed a controlled release profile and could be deposited on the osseous spiral lamina. We considered that the bovine serum albumin nanoparticles may have potential applications in the field of local drug delivery in the treatment of inner ear disorders.
...NEW YORK April 5 2011 /- Reportlinker.com announces tha...a href http://www.reportlinker.com/p0203552/Transdermal-Drug-Deliver...a href http://www.reportlinker.com/p0203552/Transdermal-Drug-Deliver...This report deals with transdermal drug delivery - an approach used to...,Reportlinker,Adds,Transdermal,Drug,Delivery,-,Technologies,,Markets,,and,Companies,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Discuss and stay updated on the latest in drug development, diagnostics at clinical pharmacy events, industrial pharmacy conferences, medicinal chemistry meetings at Abu Dhabi in 2020, 2021 from Thailand, Russia, India, Philippines, China
Access submits additional patent applications for Cobalamin-mediated oral medication delivery technology ACCESS PHARMACEUTICALS, INC. , a biopharmaceutical firm leveraging its proprietary drug-delivery platforms to build up treatments in regions of oncology, cancers supportive diabetes and care, announced it has submitted extra patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global best-100 injectable drugs, as a result of the growing curiosity surrounding the companys proprietary oral delivery technology. The CobOral branding and additional patent filings reflect the high level of interest from partners in our CobOral and CobaCyte medication delivery platforms, stated Jeffrey B. Davis, President and CEO, Gain access to Pharmaceuticals, Inc. Related StoriesNew RNA check of blood platelets can be used to identify location of cancerStudy shows rare HER2 missense mutations usually do not spread breasts cancer on their ownSausages With ...
1.2.5 Nanotubes. 1.2.6 Others. 1.3 Applications of Nanotechnology Drug Delivery. 1.3.1 Neurology. 1.3.2 Oncology. 1.3.3 Cardiovascular/Physiology. 1.3.4 Anti-inflammatory/Immunology. 1.3.5 Anti-infective. 1.3.6 Others. 1.4 Market Segment by Regions. 1.4.1 North America. 1.4.2 China. 1.4.3 Europe. 1.4.4 Southeast Asia. 1.4.5 Japan. 1.4.6 India. 2 Manufacturing Cost Structure Analysis of Nanotechnology Drug Delivery. 2.1 Raw Material and Suppliers. 2.2 Manufacturing Cost Structure Analysis of Nanotechnology Drug Delivery. 2.3 Manufacturing Process Analysis of Nanotechnology Drug Delivery. 2.4 Industry Chain Structure of Nanotechnology Drug Delivery. Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1181360. 3 Technical Data and Manufacturing Plants Analysis of Nanotechnology Drug Delivery. 3.1 Capacity and Commercial Production Date of Global Nanotechnology Drug Delivery Major Manufacturers in 2016. 3.2 Manufacturing Plants Distribution of Global Nanotechnology Drug ...
Liposomes have been evolving as unique drug carriers for realizing enhanced efficacy and/or reduced toxicity.1) Currently, several liposomal drug delivery systems are on the market, and practically all of them are administered parenterally. Liposomes are also investigated for oral delivery, especially for active ingredients with extremely low oral bioavailability, such as poorly soluble compounds. The aim of this project is to study the mechanisms underlying the bioavailability improvement of poorly soluble compounds entrapped in liposomes as oral drug delivery systems. We will start by studying the mechanisms of liposome digestion and drug solubilization and the efficiency of subsequent association of the entrapped compounds into mixed micelles, using a highly relevant in vitro human digestion model and dedicated analysis methods.2)3)4) In the second part of the project, we will study the permeability of the compounds after in vitro digestion, using an in vitro permeability model consisting of ...
Article Preparation and characterisation of 5-fluorouracil containing PLGA nanospheres coated with chitosan, for drug delivery. The aim of this study was to design a new Drug Delivery System (DDS) based on poly (lactide-co-glycolide) (PLGA) biodegrad...
The present invention comprises a transdermal drug delivery device comprising a reservoir comprising a releasably stored dosage of a pharmaceutically active agent and a translucent film adjacent to at least a portion of the reservoir, wherein the translucent film comprises at least one inorganic ultraviolet-absorbing compound. The present invention also comprises a method of drug delivery to a mammal using such devices.
Objective: Biologicals targeting epidermal growth factor (EGF) and interleukin 13 receptors not only react with overexpressed markers on cancer cells but also react with receptors on normal cells. Because we developed novel bispecific ligand-directed toxins synthesized by cloning EGF and interleukin 13 on the same molecule with toxin, our objective was to determine whether we could block normal receptors while still targeting receptors overexpressed on cancer cells, thereby decreasing toxicity while maintaining efficacy. Methods: A method, toxicity blocking (ToxBloc), was developed in which a bolus intraperitoneal dose of recombinant EGF13 (without toxin) was given to mice approximately 15 to 20 minutes before DTEGF13. Experiments were then performed to determine whether the maximal tolerated dose (MTD) was reduced and whether we were still able to eliminate progression of aggressive human, metastatic, pancreatic cancer induced by orthotopic injection (OT) in nude mice. Results: ToxBloc ...
New drug-delivery systems have remained a challenge for pharmaceutical scientists due to the use of expensive polymers and the low loading capacity of prepared nanoparticles. There is pressure to develop formulations that contain not only cheaper materials but also have controlled-release properties. Halloysite nanotubes (HNTs) are a naturally occurring clay mineral similar to kaolin, possessing a special particle shape in the form of an ultramicroscopic multilayered hollow cylinder. Its uses encompass a wide range in anticancer therapy, sustained- and controlled-release drug-delivery systems, cosmetics, delivery of proteins, vaccines and genes. These advantages are due to its biocompatibility, significant mechanical strength and natural availability. The surfaces of the tubules can be modified by coating different polymers for application in the drug-delivery system. This review is focused on the various aspects of HNTs such as structure, properties, loading methods, applications and ...
Pulmonary segment covers metered dose inhalers, dry-powder inhalers and nebulizers; this segment is growing at the highest CAGR of 11.8%. The transdermal technology market is divided into two types, namely, passive drug delivery and active drug delivery. Passive delivery is further categorized into reservoir system and matrix system, while active delivery is further categorized into iontophoresis, microporation and other technologies such as electroporation, sonophoresis and dermal ablation. Injectable technology market is classified as conventional injection, self injection, and other injection devices. Conventional devices include fillable syringes and prefilled syringes, whereas self injection devices include needle free injectors, auto-injectors, and pen injectors ...
Lectins are carbohydrate recognizing proteins originating from diverse origins in nature, including animals, plants, viruses, bacteria and fungus. Due to their exceptional glycan recognition property, they have found many applications in analytical chemistry, biotechnology and surface chemistry. This manuscript explores the current use of lectins for cancer diagnosis and therapy. Moreover, novel drug delivery strategies aiming at improving lectins stability, reducing their undesired toxicity and controlling their non-specific binding interactions are discussed. We also explore the nanotechnology application of lectins for cancer targeting and imaging. Although many investigations are being conducted in the field of lectinology, there is still a limited clinical translation of the major findings reported due to lectins stability and toxicity concerns. Therefore, new investigations of safe and effective drug delivery system strategies for lectins are warranted in order to take full advantage of these
In this work, new efficient drug delivery systems based on cellulose nanofiber-titania nanocomposites grafted with three different types of model drugs such as diclofenac sodium, penicillamine-D and phosphomycin were successfully synthesized and displayed distinctly different controlled long-term release pro
Doctors in Boston may have found a way around one of the biggest limitations of chemotherapy in patients with malignant mesothelioma.
9780444820273 Advances in Drug Delivery Systems, 6: Proceedings of the Sixth International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City,,books, textbooks, text book
Pioneering new treatment category - site-specific delivery of drugs to the brain MIDDLEBURG, Va., and DENVER, April 28, 2011 /PRNewswire-USNewswire/ -- Epilepsy Therapy Project (ETP), a non-profit
ABSTRACT. Buccal administration of drug provides a convenient route of administration for both systemic and local drug actions. The preferred site for retentive oral transmucosal delivery systems and for sustained and controlled release delivery device is the buccal mucosa. Rapid developments in the field of molecular biology and gene technology resulted in generation of many macromolecular drugs including peptides, proteins, polysaccharides and nucleic acids in great number possessing superior pharmacological efficacy with site specificity and devoid of untoward and toxic effects. However, the main impediment for the oral delivery of such drugs as potential therapeutic agents is their extensive presystemic metabolism, instability in acidic environment resulting into inadequate and erratic oral absorption. Direct access to the systemic circulation through the internal jugular vein bypasses drug from the hepatic first pass metabolism leading to high bioavailability. The objective of this article ...
Infections caused by microorganisms like bacteria, fungi, etc. are the main obstacle in healing processes. Conventional antibacterial administration routes can be listed as oral, intravenous/intramuscular, topical and inhalation. These kinds of drug administrations are faced with critical vital issues such as; more rapid delivery of the drug than intended which can result in bacterial resistance, dose related systemic toxicity, tissue irritation and finally delayed healing process that need to be tackled. Recently, studies have been focused on new drug delivery systems, overcoming resistance and toxicological problems and finally localizing the molecules at the site of action in a proper dose. In this regard, many nanotechnological approaches such as nanoparticulate therapeutic systems have been developed to address accompanying problems mentioned above. Among them, drug loaded electrospun nanofibers propose main advantages like controlled drug delivery, high drug loading capacity, high ...
The present work aims at computational analysis of environmentally responsive hydrogels with enormous prospective in the formulation aspect of drug delivery systems. The drug delivery potential of hydrogels to the targets is owing to the specific stimuli responsive nature of the hydrogels. The environmental factors looked upon in the study are changes in pH, alteration of temperature and glucose concentration rise originated in the body as a result of various disease conditions. Polymers, synthetic polypeptides and dendrimers have been used in the present work to study the feasibility of drug delivery. The computational methods have been used to formulate polymer properties, pharmacokinetics and toxicity studies. Diverse interactions approximating electrostatic, hydrophobic and hydrogen bond interactions acquire place during incorporation of drugs within the polymer and dendrimers. The covalent and electrostatic interactions between a drug and the surface of polymer and dendrimer have been ...
TY - JOUR. T1 - Excipient-free porphyrin/SN-38 based nanotheranostics for drug delivery and cell imaging. AU - Yuan, Ye. AU - Bo, Ruonan. AU - Jing, Di. AU - Ma, Zhao. AU - Wang, Zhongling. AU - Lin, Tzu yin. AU - Dong, Lijie. AU - Xue, Xiangdong. AU - Li, Yuanpei. PY - 2020/1/1. Y1 - 2020/1/1. N2 - Nanotheranostics with comprehensive diagnostic and therapeutic capabilities show exciting cancer treatment potentials. Here, we develop an excipient-free drug delivery system for cancer diagnosis as well as therapy, in which a near infra-red photosensitizer and a chemotherapeutic drug can be self-delivered without any carriers. The building block of the drug delivery system was synthesized by covalently conjugating four anticancer drugs (7-ethyl-10-hydroxy-camptothecin, SN-38) with a photosensitizer (porphyrin) via hydrolyzable ester linkage, which endows the drug delivery system with 100% active pharmaceutical ingredients, excellent imaging, and therapeutic functionalities. The conjugates can ...
Tumor-targeted drug delivery systems and uses thereof - The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of ...
Background: The use of neo-adjuvant chemotherapy in treating osteosarcoma has improved patients average 5 year survival rate from 20% to 70% in the past 30 years. However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy. Methodology/Principal Findings: In order to overcome both the dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure resulting from MDR, we designed and evaluated a novel drug delivery system for MDR1 siRNA delivery. Novel biocompatible, lipid-modified dextran-based polymeric nanoparticles were used as the platform for MDR1 siRNA delivery; and the efficacy of combination therapy with this system was evaluated. In this study, multi-drug resistant osteosarcoma cell lines (KHOSR2 and U-2OSR2) were treated with the MDR1 siRNA nanocarriers and MDR1 protein (P-gp) expression, drug retention, and immunofluoresence were analyzed. Combination therapy of
0006] According to one aspect an assembly for a drug delivery device is provided. The assembly may comprise a housing. The assembly may comprise a rotation member. The rotation member may be adapted to be rotated with respect to the housing in a first rotational direction for delivering a dose of a drug. The first rotational direction may be counter-clockwise, for example. The assembly may comprise a drive member. The drive member may be, preferably releasably, coupleable to the rotation member for delivering the dose. The assembly may comprise at least one correction member. In a delivery mode, the drive member and the rotation member are expediently coupled such that the drive member follows rotational movement of the rotation member in the first rotational direction due to mechanical interaction of the rotation member and the drive member, e.g. the rotation member and the drive member may be rotationally locked. In the delivery mode, the rotation member and, hence, the drive member may rotate ...
In this work, novel nanostructured core-shell poly(ethylene glycol) (PEG)-polyhedral oligosilsesquioxane (POSS) nanoparticles were used to encapsulate insulin as new drug delivery carriers. The morphologies, particle size and ζ potential of the pure nanostructured core-shell PEG-POSS and the corresponding insulin-loaded PEG-POSS nanoparticles were investigated by transmission electron microscopy (TEM) and laser diffraction particle sizer. TEM analysis demonstrated that pure and insulin-loaded self-assembled PEG-POSS nanoparticles were of spherical shape with core-shell nanostructure, and were well-dispersed and uniform in size distribution. Insulin release test showed that insulin was well-protected inside PEG-POSS nanoparticles at gastric pH for 2hrs, and was released at intestinal pH (pH 6-7) where the absorption and activation of the drug are necessary. We therefore believe that such nanostructured PEG-POSS nanoparticles could be useful as a potential carrier for insulin drug delivery systems.
The explicit use of colon-specific drug delivery systems is for the local treatment of colon diseases such as ulcerative colitis. Some efficient therapeutic systems, primarily prodrugs and polymeric carriers of salicylate derivatives, have been developed and commercialized during the past 20 years. Speculating that the colon is a superior organ for peptide drug absorption after oral ingestion, many studies indicate that colon-specific drug carriers may potentially be used for the delivery of peptide drugs to that organ. This notion stems from the assumption that the overall proteolytic activity in the colon is lower than and different from the proteolytic activity in the small intestine. For example, it has been found that the degradation rate of albumin, azoalbumin casein, azocasein and collagen in human ileal effluent was faster than the degradation rate in fecal slurries. Other studies, in which the degradation rates of insulin and insulin B-chain in the small and large intestine of the ...
SMi Group announces the 15th Annual Controlled Release Delivery Conference in London on March 21st - 22nd 2018. As physicians continue to request drugs which have a reduced dosage requirement, higher action times and assist in simplifying treatment schedules for patients, the focus of the pharmaceutical industry is continually moving towards innovative controlled release delivery technologies, which improve drug transport to the target.. This years event will bring together industry experts from pharmaceutical companies, regulatory agencies and biotechs to analyze and evaluate the latest advancements in Controlled Release Delivery, including the addressing formulation challenges of Abuse-Deterrent and oral lipid based Formulations, targeting controlled release delivery with Polymer Nanoparticles and how to overcome the additional challenges in controlled release delivery for pediatric medicine.. With the Oral Controlled Release Drug Delivery Technology Market expected to be worth $ 50,000 Mn in ...
Global market for implantable drug delivery devices was calculated at USD 11.6 billion and is expected to grow at a CAGR of 8.8% from 2012 to 2018, to reach an estimated value of USD 21.1 billion in 2018. The North American implantable drug delivery devices market share held majority of the market share in 2011.
Objectives: Direct pulp capping is a treatment for preserving the vital pulp. However, a satisfactory material for caries-exposed inflamed pulp in permanent teeth is not currently available. Thus, a biologically-based material that promotes the continued formation of a new dentin-pulp complex is needed. A hydrogel drug delivery vehicle is a promising material, however its cytotoxicity has barely been explored. The aim of this study is to evaluate the cytotoxicity of a hydrogel drug delivery vehicle and its components in a cell culture system in vitro. Methods: The hydrogel solution was prepared by mixing poly(ethylene glycol)maleate-citrate (45% w/v)[PEGMC], acrylic acid (5% w/v)[AA], 2,2-Azobis(2-methylpropionamidine) dihydrochloride photoinitiator (0.1% w/v)[AAPH], and deionized water. Various concentrations of the hydrogel and its components were prepared in the cell culture medium. L929 cells were seeded into 96-well plates at 3x103 cells/well and cultured with each concentration of the ...
Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancer Jinjin Shi, Zhenzhen Wang, Lei Wang, Honghong Wang, Lulu Li, Xiaoyuan Yu, Jing Zhang, Rou Ma, Zhenzhong ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, People's Republic of ChinaAbstract: Fullerene (C60) has shown great potential in drug delivery. In this study we exploited modified fullerene (diadduct malonic acid-fullerene-Asn-Gly-Arg peptide [DMA-C60-NGR]) as an antitumor drug carrier in order to build a new tumor-targeting drug delivery system. We also investigated the synergistic enhancement of cancer therapy using photodynamic therapy (PDT) induced by DMA-C60-NGR and 2-methoxyestradiol (2ME). Cytotoxicity tests indicated that DMA-C60-NGR had no obvious toxicity, while our drug delivery system (DMA-C60-2ME-NGR) had a high inhibition effect on MCF-7 cells compared to free 2ME. The tumor-targeting drug delivery system could efficiently cross cell
Inorganic matrices and biopolymers have been widely used in pharmaceutical fields. They show properties such as biocompatibility, incorporation capacity, and controlled drug release, which can become more attractive if they are combined to form hybrid materials. This work proposes the synthesis of new drug delivery systems (DDS) based on magnesium phyllosilicate (Talc) obtained by the sol-gel route method, the biopolymer chitosan (Ch), and the inorganic-organic hybrid formed between this matrix (Talc + Ch), obtained using glutaraldehyde as a crosslink agent, and to study their incorporation/release capacity of amiloride as a model drug. The systems were characterized by X-ray diffraction (XRD), Therma analysis TG/DTG, and Fourier-transform infrared spectroscopy (FTIR) that supported the DDSs formation. The hybrid showed a better drug incorporation capacity compared to the precursors, with a loading of 55.74, 49.53, and 4.71 mg g-1 for Talc + Ch, Talc, and Ch, respectively. The release assays ...
University of Delaware Professor Kristi Kiick is leading collaborative research to create new drug delivery systems with the potential to improve treatment for diseases that affect connective tissues, such as osteoarthritis or rheumatoid arthritis, which is an autoimmune disease.. The UD researchers have devised tiny cargo-carrying systems many times smaller than a human hair. These systems, or carriers, are made from molecules called peptides that help provide structure for cells and tissues.. The research team is working to program these nanoparticle carriers to selectively bind to degrading collagen in the body. Collagen is a protein that helps plump up or provide structure to connective tissue-everything from our skin to our bones, tendons and ligaments.. When collagen degrades, as a result of disease or injury, the nanoparticles designed by the Kiick lab can attach and remain at the injury site longer than many current treatment options. This allows for the possibility of delivering ...
Grant Number: JPMJER1101. The biologics including proteins, nucleic acids and extracellular vesicles (exosomes) have been attracted attention as innovative pharmaceutical products in advanced nanomedicine. In this project, new bio-nanotransporters (bio-inspired nanoparticles) have been developed for new drug delivery systems(DDS) especially for such biologics to apply cancer immuno-therapies, vaccines and tissue engineering. We proposed nanogel tectonics using self-assembled nanogels as building blocks to construct multi functional well-controlled gel biomaterials, e.g. artificial cellular matrix and tissue scaffold. Proteoliposomes were efficiently prepared by cell-free membrane protein synthesis with liposome chaperone (artificial cell method) for bio-analysis and DDS. New strategy for functionalization of exosomes has been developed by fusion with nanogel engineering and liposome engineering. Functions of T cell derived exosomes for cancer microenvironment were newly found and the exosomes ...
Nanomedicine is an emerging area in the medical field, particularly in the treatment of cancers. Nanostructured lipid carrier (NLC) was shown to be a good nanoparticulated carrier for the delivery of tamoxifen (TAM). In this study, the tamoxifen-loaded erythropoietin-coated nanostructured lipid carriers (EPO-TAMNLC) were developed to enhance the anti-cancer properties and targetability of TAM, using EPO as the homing ligand for EPO receptors (EpoRs) on breast cancer tissue cells. Tamoxifen-loaded NLC (TAMNLC) was used for comparison. The LA7 cells and LA7 cell-induced rat mammary gland tumor were used as models in the study. Immunocytochemistry staining showed that LA7 cells express estrogen receptors (ERs) and EpoRs. EPO-TAMNLC and TAMNLC significantly (p|0.05) inhibited proliferation of LA7 in dose- and time-dependent manner. EPO-TAMNLC induced apoptosis and G0/G1 cell cycle arrest of LA7 cells. Both drug delivery systems showed anti-mammary gland tumor properties. At an intravenous dose of 5 mg kg-1
Tamara Minko is Professor of Pharmaceutics at the Ernest Mario School of Pharmacy in the Department of Pharmaceutics at Rutgers, The State University of New Jersey. Prof. Minkos research interests include drug delivery; biopharmaceutics; nanotechnology for cancer detection and treatment; molecular targeting; antisense oligonucleotides, siRNA and peptides in cancer therapy; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs: apoptosis and necrosis, signal transduction, antiapoptotic cellular defensive mechanisms; use of macromolecules for drug delivery; preclinical evaluation of anticancer drugs; tumor hypoxia; modulation of cell death mechanisms during hypoxia.Speaking in the special symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.
CORVALLIS, Ore. - Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.. This advance in nanomedicine combines the extraordinarily small size of nanoparticles, existing cancer drugs, and small interfering RNA (siRNA) that shut down the ability of cancer cells to resist attack.. The combination of these forces resulted in the virtual disappearance of lung tumors in experimental animals.. Lung cancer is the leading cancer killer in both men and women. Despite advances in surgery, chemotherapy still plays a major role in its treatment. However, that treatment is constrained by the toxic effects of some drugs needed to combat it and the difficulty of actually getting those drugs into the lungs.. The findings were made by Oleh Taratula at Oregon State University and ...
This chapter aims to provide the readers a comprehensive review of the current trends and approaches used in the development of ocular drug delivery systems. After the introduction to the topic, the c